GLP-2 (T)
GLP-2 (T)
MUG-001
$ 12
A dual GIP/GLP-1 receptor agonist By activating both GIP and GLP-1 pathways simultaneously, it achieves superior weight loss vs. semaglutide alone. Improves insulin secretion, reduces appetite, and enhances fat metabolism.
192 in stock
Benefits
✓ Superior weight loss (up to 22–25% body weight)
✓ Better glycemic control than GLP-1 monotherapy
✓ Improved triglycerides and HDL cholesterol
✓ Reduced liver fat
✓ Cardiovascular benefit signals in trials
✓ Better glycemic control than GLP-1 monotherapy
✓ Improved triglycerides and HDL cholesterol
✓ Reduced liver fat
✓ Cardiovascular benefit signals in trials
Side Effects
• Cortisol and prolactin increase (significant)
• Increased appetite
• Water retention
• Desensitization with prolonged use (requires cycling)
• Fatigue
• Injection site reactions
• Increased appetite
• Water retention
• Desensitization with prolonged use (requires cycling)
• Fatigue
• Injection site reactions
Half Life
5 Days
Note
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Composition and dosing ratios are vendor-defined and not independently verified.
GLP-2 (T)
MUG-001
$ 12
A dual GIP/GLP-1 receptor agonist By activating both GIP and GLP-1 pathways simultaneously, it achieves superior weight loss vs. semaglutide alone. Improves insulin secretion, reduces appetite, and enhances fat metabolism.
192 in stock
FOR LABORATORY / RESEARCH USE ONLY. Not for human use or consumption. Not for animal or veterinary use or testing. Not a drug, food, cosmetic, or medical device, and not evaluated or approved by the FDA. Composition and dosing ratios are vendor-defined and not independently verified.
✓ Superior weight loss (up to 22–25% body weight)
✓ Better glycemic control than GLP-1 monotherapy
✓ Improved triglycerides and HDL cholesterol
✓ Reduced liver fat
✓ Cardiovascular benefit signals in trials
✓ Better glycemic control than GLP-1 monotherapy
✓ Improved triglycerides and HDL cholesterol
✓ Reduced liver fat
✓ Cardiovascular benefit signals in trials
5 Days